Richard Osborne Day

89PUBLICATIONS
210CO-AUTHORS
Public economics - publicly provided goodsMajor global burdens of diseaseGene and molecular therapyMolecular medicinePatient safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (89)

|Oct 12, 2026
The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia's Pharmaceutical Benefits Scheme.

|Aug 17, 2026
Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes.

|May 15, 2026
Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.

|May 11, 2026
Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report.

|Mar 20, 2026
Achieving effective medicines governance: guiding principles for the roles and responsibilities of Medicines and Therapeutics Committees in Australian hospitals.

Lisa Crisp, Richard Day, Anita Shutt

|Feb 25, 2026
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses.

Stephanie Mathieson, Joshua R Zadro, Sujita W Narayan

Pageof 15

Frequent Collaborators

23 joint publications

Sophie Stocker

12 joint publications

Jane Ellen Carland

11 joint publications

Melissa T Baysari

10 joint publications

Matthew J Coleshill